Candriam SCA’s Fulcrum Therapeutics FULC Stock Holding History

Candriam SCA’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-101,337	Closed	-$266K	–	781
2023 Q1	$266K	Buy	+101,337	New	+$908K	﹤0.01%	859

Other funds holding FULC

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Candriam SCA's FULC Position: Q2 2023 in Review

Candriam SCA sold out of Fulcrum Therapeutics (FULC) in Q2 2023, closing a stake of 101,337 shares — an estimated $266K sold.

Candriam SCA first reported a position in FULC in Q1 2023 and held it in 1 quarter. The position peaked at $266K in Q1 2023. 88 funds tracked by Wall St. Rank hold FULC as of Q2 2023.

Candriam SCA reported no remaining Fulcrum Therapeutics position as of Q2 2023 after selling out during the quarter.
Candriam SCA sold 101,337 Fulcrum Therapeutics shares in Q2 2023, an estimated $266K.
Candriam SCA first reported a position in Fulcrum Therapeutics in Q1 2023 and held it in 1 quarter.
Candriam SCA's Fulcrum Therapeutics position peaked at $266K in Q1 2023.
88 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2023.

Based on Candriam SCA's 13F filing for Q2 2023, filed 8 Aug 2023.